Invasive breast carcinoma is a type of breast cancer where abnormal cells break through the lining of milk ducts or lobules and spread into surrounding breast tissue. Treatment aims to remove or destroy cancer cells, prevent the disease from spreading, and help patients maintain the best possible quality of life.

How Treatment Decisions Are Made for Invasive Breast Carcinoma

When someone receives a diagnosis of invasive breast carcinoma, the treatment journey begins with careful planning. Doctors consider many different pieces of information before recommending the best approach for each person. The type of cancer cells, the size of the tumor, whether the cancer has spread to nearby lymph nodes, and the patient’s overall health all play important roles in these decisions.^[2][3]

Medical teams also examine whether cancer cells have special receptors on their surface. These receptors are protein molecules that can attach to hormones like estrogen and progesterone, or to a protein called HER2. Knowing which receptors are present helps doctors choose treatments that specifically target those receptors, making therapy more effective.^[10][15]

The stage of the disease is another critical factor. Stage refers to how large the tumor is and how far it has traveled from where it started. Early stage invasive breast carcinoma means the cancer is still relatively small and has not spread far, while advanced stages indicate larger tumors or cancer that has reached other parts of the body. Treatment plans differ significantly depending on the stage.^[2][13]

Most women diagnosed with invasive breast carcinoma are age 55 or older, though the disease can affect younger women as well. Age and whether a woman has gone through menopause can influence which treatments are most appropriate. Personal preferences about surgery options and lifestyle considerations also matter when creating a treatment plan.^[10][8]

Standard Treatment Approaches

Surgery as the Primary Treatment

Surgery is typically the main treatment for invasive breast carcinoma when the cancer has not spread to distant parts of the body. There are two main surgical options, and both have similar survival rates when the cancer can be completely removed.^[2][13]

The first option is called lumpectomy or breast-conserving surgery. This operation removes the tumor and some surrounding healthy tissue while leaving most of the breast intact. Lumpectomy is usually followed by radiation therapy to destroy any remaining cancer cells in the breast area. This combination approach helps prevent the cancer from coming back.^[2][15]

The second surgical option is mastectomy, which removes the entire breast. Some women choose mastectomy because it eliminates the need for radiation therapy in many cases. Others prefer it for peace of mind or because their tumor is too large for lumpectomy to leave good cosmetic results. Women who have a mastectomy can often have breast reconstruction surgery, either at the same time or later.^[2][13]

During surgery, doctors often perform a sentinel lymph node biopsy to check if cancer has spread to the lymph nodes under the arm. The sentinel lymph node is the first node where cancer would likely spread. If cancer is found in these nodes, more extensive lymph node removal may be necessary. This information also helps doctors determine if additional treatment is needed after surgery.^[2][15]

Radiation Therapy

Radiation therapy uses high-energy beams to kill cancer cells. Most women who have lumpectomy receive radiation therapy to the remaining breast tissue. This treatment significantly reduces the risk that cancer will return in the same breast. Radiation is typically given five days a week for several weeks, though shorter schedules are sometimes possible.^[2][13]

The radiation itself is painless and similar to getting an X-ray, just longer. However, it can cause side effects including tiredness, skin changes in the treated area that may look like sunburn, and breast swelling. These effects usually improve within a few weeks after treatment ends. Some women experience long-term changes in breast size or texture.^[2]

Chemotherapy

Chemotherapy uses drugs to kill cancer cells throughout the body. It can be given before surgery to shrink tumors, making them easier to remove. When given before surgery, it’s called neoadjuvant therapy. Chemotherapy can also be given after surgery to destroy any cancer cells that might remain in the body, reducing the risk of the cancer returning or spreading.^[2][13]

Doctors recommend chemotherapy based on several factors, including the size of the tumor, whether cancer is in the lymph nodes, how quickly the cancer cells are growing, and the receptor status of the tumor. Chemotherapy is especially important for cancers that don’t have hormone or HER2 receptors, called triple-negative breast cancer, because there are fewer other treatment options for this type.^[9][15]

Chemotherapy drugs are usually given through a vein or as pills. Treatment often involves several drugs given in cycles, with rest periods in between to allow the body to recover. Common side effects include hair loss, nausea, fatigue, increased risk of infection, and mouth sores. Most of these side effects go away after treatment ends, though some effects may persist longer.^[2]

Hormone Therapy

When breast cancer cells have estrogen or progesterone receptors, they are called hormone receptor-positive cancers. These cancers use hormones to grow. Hormone therapy works by blocking hormones or lowering hormone levels in the body, which can slow or stop cancer growth.^[2][15]

Several different hormone therapy medications are used. Tamoxifen is a pill taken daily that blocks estrogen receptors in breast cells. It can be used in both premenopausal and postmenopausal women and is typically taken for five to ten years. Common side effects include hot flashes, vaginal dryness, and a slightly increased risk of uterine cancer and blood clots.^[15]

Another group of hormone therapy drugs called aromatase inhibitors work differently by lowering the amount of estrogen in the body. These drugs, which include medications like letrozole, anastrozole, and exemestane, are only effective in postmenopausal women. They are usually taken for five to ten years. Side effects often include joint pain, bone thinning, and hot flashes.^[15]

Targeted Therapy

Targeted therapy uses drugs that attack specific features of cancer cells. One important type of targeted therapy treats cancers with high levels of the HER2 protein. HER2-positive cancers tend to grow more quickly than other breast cancers, but targeted drugs can be very effective against them.^[15]

Trastuzumab is a targeted therapy drug commonly used for HER2-positive breast cancer. It is usually given through a vein every few weeks, often combined with chemotherapy and then continued alone. Treatment typically lasts for one year. Another drug, pertuzumab, is often given together with trastuzumab and chemotherapy. These medications can cause side effects including heart problems, so doctors monitor heart function during treatment.^[15]

For postmenopausal women with hormone receptor-positive breast cancer, targeted drugs called CDK 4/6 inhibitors are often combined with hormone therapy. These drugs, including palbociclib, ribociclib, and abemaciclib, block proteins that help cancer cells divide. They can slow cancer growth and are particularly useful for advanced breast cancer.^[21]

Treatment Being Tested in Clinical Trials

Researchers continue to develop new treatments for invasive breast carcinoma through clinical trials, which are carefully controlled studies that test whether new treatments are safe and effective. Patients who participate in clinical trials may gain access to promising new therapies before they become widely available. Clinical trials are conducted in phases, each with a specific purpose.^[16]

Understanding Clinical Trial Phases

Phase I trials are small studies that test a new treatment in people for the first time. The main goal is to find out if the treatment is safe, what side effects it causes, and what dose should be used. Phase I trials usually involve 20 to 80 participants.^[16]

Phase II trials involve more people, typically 100 to 300 participants. These studies test whether the new treatment actually works against cancer and continue to evaluate safety. Researchers look at whether tumors shrink, whether the cancer stops growing, and how long patients survive.^[16]

Phase III trials are large studies that compare the new treatment to current standard treatments. These trials may involve thousands of participants and provide the strongest evidence about whether a new treatment should become standard care. Only treatments that succeed in Phase III trials typically become approved for widespread use.^[16]

Antibody-Drug Conjugates

One of the most promising areas of research involves antibody-drug conjugates, which are sometimes called “smart bombs” against cancer. These treatments combine an antibody that finds cancer cells with a chemotherapy drug that kills them. The antibody acts like a guided missile, delivering chemotherapy directly to cancer cells while sparing healthy cells.^[21]

Trastuzumab deruxtecan (brand name Enhertu) is an antibody-drug conjugate that has shown remarkable results in clinical trials. It attaches to the HER2 protein on cancer cells and releases chemotherapy inside them. In trials, this drug has helped patients with HER2-positive breast cancer whose disease had progressed despite other treatments. It has also shown promise in cancers with low levels of HER2.^[21]

Another antibody-drug conjugate called sacituzumab govitecan (brand name Trodelvy) targets a different protein found on many breast cancer cells. Clinical trials have shown it helps patients with triple-negative breast cancer and some hormone receptor-positive cancers. Side effects can include diarrhea, nausea, low white blood cell counts, and lung inflammation, but many patients tolerate the treatment well.^[21]

Immunotherapy

Immunotherapy helps the body’s own immune system recognize and attack cancer cells. Cancer cells sometimes hide from the immune system by using proteins that act like brakes on immune responses. Immunotherapy drugs can release these brakes, allowing immune cells to attack cancer.^[21]

For triple-negative breast cancer, a type that has been difficult to treat, immunotherapy drugs called checkpoint inhibitors are being tested in combination with chemotherapy. Pembrolizumab is one such drug that has shown benefit in clinical trials. It works by blocking a protein called PD-1 that cancer cells use to avoid immune attack. Research continues to identify which patients benefit most from immunotherapy.^[21]

PARP Inhibitors

For women with mutations in genes called BRCA1 or BRCA2, a class of drugs called PARP inhibitors offers new hope. These genes normally help repair damaged DNA in cells. When they don’t work properly, cells have trouble fixing DNA damage, and cancer is more likely to develop. PARP inhibitors block another DNA repair pathway, making it even harder for cancer cells with BRCA mutations to survive.^[21]

Olaparib and talazoparib are PARP inhibitors that have been tested in clinical trials for breast cancer with BRCA mutations. Studies have shown these drugs can slow cancer growth and help patients live longer without their disease worsening. They are taken as pills and generally cause fewer side effects than chemotherapy, though they can cause nausea, fatigue, and low blood counts.^[21]

New Targeted Therapies

Researchers are testing drugs that block specific molecular pathways cancer cells use to grow and survive. PIK3CA inhibitors are one example. The PIK3CA gene, when mutated, helps cancer cells grow. A drug called alpelisib blocks the abnormal protein made by this mutated gene. Clinical trials have shown it can help patients with hormone receptor-positive, HER2-negative breast cancer who have PIK3CA mutations, especially when combined with hormone therapy.^[21]

AKT inhibitors and mTOR inhibitors block other parts of the same growth pathway. These drugs are being studied in combination with hormone therapy for advanced breast cancer. Early results suggest they may help overcome resistance to hormone therapy, allowing these treatments to work longer.^[21]

New oral medications called selective estrogen receptor degraders, or SERDs, are being developed to more effectively block estrogen receptors. Unlike tamoxifen, which blocks the receptor, SERDs destroy it completely. Elacestrant (brand name Orserdu) is one such drug that has shown promise in clinical trials for patients whose cancer has progressed on other hormone therapies. Additional SERDs are in development, with trials ongoing in the United States, Europe, and other locations.^[21]

Accessing Clinical Trials

Clinical trials for invasive breast carcinoma are being conducted at major cancer centers and hospitals throughout the United States, Europe, and many other countries. Patients interested in clinical trials should discuss options with their oncologist, who can help determine which trials might be appropriate. Eligibility depends on factors including cancer type, stage, previous treatments, and overall health.^[16]

Most Common Treatment Methods

• Surgery
  • Lumpectomy removes the tumor and surrounding tissue while preserving most of the breast
  • Mastectomy removes the entire breast and may be followed by reconstruction
  • Sentinel lymph node biopsy checks whether cancer has spread to lymph nodes
• Radiation Therapy
  • Uses high-energy beams to destroy cancer cells in the breast area
  • Usually given after lumpectomy for several weeks
  • Helps prevent cancer from returning in the same breast
• Chemotherapy
  • Uses drugs to kill cancer cells throughout the body
  • Can be given before surgery to shrink tumors or after surgery to destroy remaining cancer cells
  • Particularly important for triple-negative breast cancer and high-risk cancers
• Hormone Therapy
  • Blocks hormones or lowers hormone levels to slow cancer growth
  • Only effective for hormone receptor-positive cancers
  • Includes medications like tamoxifen for all women and aromatase inhibitors for postmenopausal women
  • Usually taken for five to ten years
• Targeted Therapy
  • Attacks specific features of cancer cells such as HER2 protein
  • Includes drugs like trastuzumab and pertuzumab for HER2-positive cancers
  • CDK 4/6 inhibitors combined with hormone therapy for hormone receptor-positive cancers
  • Antibody-drug conjugates like trastuzumab deruxtecan and sacituzumab govitecan
• Immunotherapy
  • Helps the immune system recognize and attack cancer cells
  • Checkpoint inhibitors like pembrolizumab for triple-negative breast cancer
  • Often combined with chemotherapy
• PARP Inhibitors
  • Block DNA repair in cancer cells with BRCA1 or BRCA2 mutations
  • Include drugs like olaparib and talazoparib
  • Taken as pills with fewer side effects than traditional chemotherapy

Managing Side Effects and Quality of Life

All breast cancer treatments can cause side effects, though everyone experiences them differently. Managing these effects is an important part of care. Doctors can prescribe medications to reduce nausea from chemotherapy, creams for skin changes from radiation, and pain relievers when needed. Being open with the medical team about side effects helps them adjust treatment or provide supportive care.^[7]

Fatigue is one of the most common side effects across all treatments. Rest when needed, but gentle physical activity like short walks can actually help with energy levels. Eating a balanced diet with enough protein helps the body heal and maintain strength during treatment. Some patients find that breaking meals into smaller, more frequent portions helps when nausea is a problem.^[24]

Emotional well-being matters just as much as physical health during breast cancer treatment. Many patients find support groups helpful, whether meeting in person or connecting online with others going through similar experiences. Professional counseling can provide tools for managing anxiety and adjusting to life changes. Family and friends often want to help but may not know how, so being specific about needs can make it easier for them to provide meaningful support.^[18]